Anúncio
Anúncio

SRPT

SRPT logo

Sarepta Therapeutics,, Inc. Common Stock

23.83
USD
Patrocinado
+0.68
+2.92%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

23.77

-0.06
-0.26%

Relatórios de Lucros SRPT

Rácio de surpresa positiva

SRPT separação 18 de 40 últimas estimativas.

45%

Próximo Relatório

Data do Próximo Relatório
24 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$388.56M
/
-$1.44
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-2.70%
/
+14300.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-40.99%
/
-196.00%

Sarepta Therapeutics,, Inc. Common Stock earnings per share and revenue

On 03 de nov. de 2025, SRPT reported earnings of -0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.83 USD, resulting in a 98.80% surprise. Revenue reached 399.36 milhão, compared to an expected 345.48 milhão, with a 15.59% difference. The market reacted with a -33.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 26 analistas forecast an EPS of -1.44 USD, with revenue projected to reach 388.56 milhão USD, implying an aumentar of 14300.00% EPS, and diminuir of -2.70% in Revenue from the last quarter.
FAQ
For Q3 2025, Sarepta Therapeutics,, Inc. Common Stock reported EPS of -$0.01, beating estimates by 98.8%, and revenue of $399.36M, 15.59% above expectations.
The stock price moved down -33.74%, changed from $24.45 before the earnings release to $16.20 the day after.
The next earning report is scheduled for 24 de fev. de 2026.
Based on 26 analistas, Sarepta Therapeutics,, Inc. Common Stock is expected to report EPS of -$1.44 and revenue of $388.56M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio